Clinical Trials Browser

Neoplasm Metastasis × Fluorouracil × Head & Neck × Clear all

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT01864772 2022-08-19

ELANFIT

Phase 2 Completed

85 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT04890522 2021-05-18

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Phase 2/3 Not yet recruiting

622 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01360827 2014-06-17

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Terminated

13 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis

NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2/3 Completed

568 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Clinical Trials

AB122 Platform Study

ELANFIT

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma